Daniel O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

Play-by-play of Gilead­'s $21B Im­munomedics buy­out de­tails a fren­zied push — and mints a new biotech bil­lion­aire

Im­munomedics had not re­al­ly been look­ing for a buy­out when the year be­gan. Ex­cit­ed by its BLA for Trodelvy, sub­mit­ted to the FDA in late …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.